Vivek Subbiah MD

Oncology•Nashville, TN

Endocrine Cancer, Hematologic Oncology, Sarcoma

Chief, Early-Phase Drug Development, SCRI

Join to View Full Profile

335 24th Ave N #200Nashville, TN 37203
Phone+1 615-329-7640

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2012
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 2008 - 2011
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine/Pediatrics, 2004 - 2008
Sri Ramachandra Medical CollegeClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
TN State Medical License 2023 - 2026
TX State Medical License 2010 - 2025
OK State Medical License 2020 - 2021
OH State Medical License 2004 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trial of Curcumin in Advanced Pancreatic Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2012 May 14
ACTIVE_NOT_RECRUITING
PHASE1
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer Start of enrollment: 2012 Dec 18
Completed
Phase 1
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma Start of enrollment: 2013 Oct 16
Completed
Phase 1, Phase 2
Safety and Efficacy Study of DCVax-Direct in Solid Tumors Start of enrollment: 2013 Jun 01
Unknown status
Phase 1, Phase 2
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients with Solid Tumors
COMPLETED
PHASE1
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Regorafenib and Cetuximab in Patients With Advanced Malignancy Start of enrollment: 2014 Mar 19
Completed
Phase 1
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) Start of enrollment: 2014 Sep 17
Terminated
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers Start of enrollment: 2018 Mar 12
Completed
Phase 1
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors Start of enrollment: 2018 Mar 12
Completed
Phase 1
A Study of LY3405105 in Participants With Advanced Cancer Start of enrollment: 2019 Jan 31
Terminated
Phase 1
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study Start of enrollment: 2019 Dec 14
ACTIVE_NOT_RECRUITING
PHASE2
The Registry of Oncology Outcomes Associated with Testing and Treatment Start of enrollment: 2021 May 05
COMPLETED
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors Start of enrollment: 2020 Aug 01
Recruiting
Phase 1, Phase 2
TCF-001 TRACK (Target Rare Cancer Knowledge) Study Start of enrollment: 2020 Oct 01
RECRUITING
NA
Join now to see all

Publications & Presentations

PubMed

Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras.
Vivek Subbiah, Megan Othus, Jim Palma, Branko Cuglievan, Razelle Kurzrock
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2025-06-01
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced soli...
Timothy Price, Iwona Lugowska, Sant P Chawla, Gerald Falchook, Vivek Subbiah
BMJ Open. 2025-05-02
Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial.
Mirella Nardo, Camila Braganca Xavier, Bettzy Stephen, Jeffrey A How, Justin Moyers
Journal of Immunotherapy and Precision Oncology. 2025-05-01

Lectures

Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

With a Whisper and a Splash: CGP Is Taking Root in Oncology Clinics WorldwideFebruary 11th, 2025
Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 TherapyJanuary 30th, 2025
Precision Oncology Summit to Feature Novel Therapies, Latest Cancer Treatment AdvancesJanuary 1st, 2025
Join now to see all

Vivek Subbiah MD

Dr. Subbiah is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.